bioAffinity Technologies, Inc.
BIAF- Exchange
- Nasdaq
- Industry
- Services-Commercial Physical & Biological Research
- SEC CIK
- 0001712762
No open-market purchases or sales by bioAffinity Technologies, Inc. insiders were filed in the last 90 days; 20 institutions reported holding it in 13F filings for Q2 2026, worth $782.5K in total; no superinvestor holds it.
Other share classesBIAFW
Q4 2022 vs. Q3 2022
How the institutions holding bioAffinity Technologies, Inc. changed between Q3 2022 and Q4 2022.
All holders in Q4 2022All holders in Q3 2022
| Measure | Q3 2022 | Q4 2022 | Change |
|---|---|---|---|
| Holders | 6 | 5 | −1 |
| Shares | 66.1K | 83.5K | +17.4K (+26.3%) |
| Value | $192.0K | $133.5K | −$58.5K (−30.5%) |
New holders (3)
Institutions that held bioAffinity Technologies, Inc. at the end of Q4 2022 but not at the end of Q3 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Financial Engines Advisors L.L.C. | 64,749 | $103.6K | 0.00% |
| Wells Fargo & Company | 27 | $43 | 0.00% |
| Morgan Stanley | 3 | $5 | 0.00% |
Sold out (4)
Institutions that held bioAffinity Technologies, Inc. at the end of Q3 2022 and filed for Q4 2022 without it.
| Institution | Shares, Q3 2022 | Value, Q3 2022 |
|---|---|---|
| Citadel Advisors LLC | 20,583 | $60.0K |
| Jane Street Group, LLC | 11,004 | $32.0K |
| Royal Bank of Canada | 1 | $0 |
| Tower Research Capital LLC (TRC) | 25 | $0 |